DDInter336 DDInter638
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling. Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes vasoconstriction and renal reabsorption of sodium ions in the kidneys. Ultimately, enalaprilat works to reduce blood pressure and blood fluid volume. Commonly marketed under the trade name Vasotec, enalapril was first approved by the FDA in 1985 for the management of hypertension, heart failure, and asymptomatic left ventricular dysfunction. It is also found in a combination product containing [hydrochlorothiazide] that is used for the management of hypertension. The active metabolite enalaprilat is also available in oral tablets and intravenous formulations for injection.
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enalapril
Celecoxib {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Enalapril
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enalapril
Celecoxib {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Fosinopril
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Celecoxib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trandolapril
Trandolapril {u} (Compound) resembles {v} (Compound) Enalapril
Celecoxib {u} (Compound) causes {v} (Side Effect) Proctalgia
Proctalgia {u} (Side Effect) is caused by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enalapril
Celecoxib {u} (Compound) causes {v} (Side Effect) Myositis
Myositis {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enalapril
Celecoxib {u} (Compound) resembles {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enalapril
Celecoxib {u} (Compound) binds {v} (Gene) CA12
CA12 {u} (Gene) regulates {v} (Gene) ATP6V1D
ATP6V1D {u} (Gene) is downregulated by {v} (Compound) Enalapril
Celecoxib {u} (Compound) resembles {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) causes {v} (Side Effect) Serum creatinine increased
Serum creatinine increased {u} (Side Effect) is caused by {v} (Compound) Enalapril
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enalapril (Compound)
Celecoxib (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Enalapril (Compound)
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Enalapril
Celecoxib (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Fosinopril (Compound) and Fosinopril (Compound) resembles Enalapril (Compound)
Celecoxib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trandolapril (Compound) and Trandolapril (Compound) resembles Enalapril (Compound)
Celecoxib (Compound) causes Proctalgia (Side Effect) and Proctalgia (Side Effect) is caused by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Enalapril
Celecoxib (Compound) causes Myositis (Side Effect) and Myositis (Side Effect) is caused by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Enalapril
Celecoxib (Compound) resembles Etoricoxib (Compound) and Etoricoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enalapril (Compound)
Celecoxib (Compound) binds CA12 (Gene) and CA12 (Gene) regulates ATP6V1D (Gene) and ATP6V1D (Gene) is downregulated by Enalapril (Compound)
Celecoxib (Compound) resembles Etoricoxib (Compound) and Etoricoxib (Compound) causes Serum creatinine increased (Side Effect) and Serum creatinine increased (Side Effect) is caused by Enalapril (Compound)